BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35848476)

  • 1. Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma.
    Al-Maghrabi J; Al-Mansouri Z; Al-Harbi A; Assidi M; Buhmeida A; Gomaa W
    Pol J Pathol; 2022; 73(1):14-20. PubMed ID: 35848476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma.
    Wang L; Pan L; Yao M; Cai Y; Dong Z; Yao D
    Oncotarget; 2016 Jul; 7(27):42150-42158. PubMed ID: 27286460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of clusterin in colorectal carcinoma in relation to clinicopathological criteria.
    Gomaa W; Al-Ahwal M; Al-Maghrabi H; Buhmeida A; Al-Qahtani M; Al-Maghrabi B; Al-Maghrabi J
    Malays J Pathol; 2017 Dec; 39(3):243-250. PubMed ID: 29279586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma.
    Al-Maghrabi J; Emam E; Gomaa W; Al-Qaydy D; Al-Maghrabi B; Buhmeida A; Abuzenadah A; Al-Qahtani M; Al-Ahwal M
    Int J Clin Exp Pathol; 2015; 8(12):15895-902. PubMed ID: 26884861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of immunostaining of Wnt signalling pathway molecules, E-cadherin and β-catenin in colorectal carcinomacolorectal carcinoma.
    Gomaa W; Al-Maghrabi H; Al-Maghrabi J
    Arab J Gastroenterol; 2021 Jun; 22(2):137-145. PubMed ID: 34088623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence.
    Al-Maghrabi J; Emam E; Gomaa W; Saggaf M; Buhmeida A; Al-Qahtani M; Al-Ahwal M
    BMC Cancer; 2015 Oct; 15():676. PubMed ID: 26459369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low expression of MUC2 is associated with longer disease-free survival in patients with colorectal carcinoma.
    Al-Maghrabi J; Sultana S; Gomaa W
    Saudi J Gastroenterol; 2019; 25(1):61-66. PubMed ID: 30226481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological study of five cases.
    Murakami T; Yao T; Yatagai N; Yamashiro Y; Saito T; Sakamoto N; Nagahara A
    Histopathology; 2020 Jan; 76(2):325-332. PubMed ID: 31429980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
    Ibrahim TR; Abdel-Raouf SM
    Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of glypican-3 and E-cadherin expressions to clinicopathological features and prognosis of mucinous and non-mucinous colorectal adenocarcinoma.
    Foda AA; Mohammad MA; Abdel-Aziz A; El-Hawary AK
    Tumour Biol; 2015 Jun; 36(6):4671-9. PubMed ID: 25619476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation.
    Cui X; Li Z; Gao PJ; Gao J; Zhu JY
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):157-63. PubMed ID: 25865688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical staining of cytokeratin 20 and cytokeratin 7 in colorectal carcinomas: Four different immunostaining profiles.
    Al-Maghrabi J; Emam E; Gomaa W
    Saudi J Gastroenterol; 2018; 24(2):129-134. PubMed ID: 29637921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.
    Yao M; Yao DF; Bian YZ; Zhang CG; Qiu LW; Wu W; Sai WL; Yang JL; Zhang HJ
    Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):289-94. PubMed ID: 21669573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
    Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
    J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Aldehyde Dehydrogenase 1A1 (ALDH1A1) as a Prognostic Biomarker in Colorectal Cancer Using Immunohistochemistry.
    Yang W; Wang Y; Wang W; Chen Z; Bai G
    Med Sci Monit; 2018 May; 24():2864-2872. PubMed ID: 29748529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients.
    Grillo PK; Győrffy B; Götte M
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1937-1955. PubMed ID: 33742285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of chemokine receptor CXCR7 in colorectal carcinoma and its prognostic significance.
    Yang D; Dai T; Xue L; Liu X; Wu B; Geng J; Mao X; Wang R; Chen L; Chu X
    Int J Clin Exp Pathol; 2015; 8(10):13051-8. PubMed ID: 26722500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.
    Wang JY; Wang XK; Zhu GZ; Zhou X; Yao J; Ma XP; Wang B; Peng T
    BMC Cancer; 2021 Apr; 21(1):462. PubMed ID: 33902495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.
    Wang L; Yao M; Pan LH; Qian Q; Yao DF
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):361-6. PubMed ID: 26256079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of arginase-1 and glypican-3 expression levels in patients after surgical intrahepatic cholangiocarcinoma resection.
    Qiang Z; Zhang H; Jin S; Yan C; Li Z; Tao L; Yu H
    World J Surg Oncol; 2021 Oct; 19(1):316. PubMed ID: 34715880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.